Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been described as a metric to quantify such patient selection bias, with short DTI being associated with adverse r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2021-08, Vol.39 (23), p.JCO2002573-2616
Hauptverfasser:	Alig, Stefan, Macaulay, Charles W, Kurtz, David M, Dührsen, Ulrich, Hüttmann, Andreas, Schmitz, Christine, Jin, Michael C, Sworder, Brian J, Garofalo, Andrea, Shahrokh Esfahani, Mohammad, Nabet, Barzin Y, Soo, Joanne, Scherer, Florian, Craig, Alexander F M, Casasnovas, Olivier, Westin, Jason R, Gaidano, Gianluca, Rossi, Davide, Roschewski, Mark, Wilson, Wyndham H, Meignan, Michel, Diehn, Maximilian, Alizadeh, Ash A
Format:	Artikel
Sprache:	eng
Schlagworte:	ORIGINAL REPORTS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!